Lilly Axes Three Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
Lilly Axes Three Therapies Amid Pipeline-in-a-Product Push for GLP-1 Read More »
